secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2022-05-27T23:59:59+00:00
Accession:  0001575872-22-000476
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Capital Acquisition Corp. announces separate trading of Class A shares and warrants starting May 31, 2022
--------------------------------------------------------------------------------

- Units from IPO of 8,250,000 units may be separated into Class A ordinary shares and warrants effective May 31, 2022.
- Each unit consists of one Class A ordinary share and one redeemable warrant to purchase one Class A share at $11.50.
- Separated shares trade under DECA and warrants under DECAW; units remain under DECAU on Nasdaq.
- No fractional warrants will be issued; holders must contact transfer agent VStock Transfer to separate units.
- Joint book-runners were US Tiger Securities, Inc. and EF Hutton; Craig-Hallum acted as qualified independent underwriter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000157587222000476/0001575872-22-000476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000157587222000476/deca-20220526.htm
  HTML page:      https://secwatch.observer/filing/0001575872-22-000476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer